Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA-33 PET/CT in Prostate Cancer
NCT06054789Unknown
- Sponsor
- Nanjing First Hospital
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga-PSMA-33 in prostate cancer (PCa), sponsored by Nanjing First Hospital. Primary endpoints: Tumor detection rate at 2 years and Standardized Uptake Value at 2 years. Status: unknown.
02
Drugs
68Ga-PSMA-33
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06054789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054789.